Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CCR3 | P51677 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576850 | 0.89 | MEN1 (0.73) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL4579363 | 0.86 | GRIN2B (0.53) | MEN1KMT2APOLBCCR3 | |
| SCHEMBL4577502 | 0.83 | KMT2A (0.63) | MEN1KMT2ASMN1; SMN2CCR3OPRM1 | |
| SCHEMBL4591294 | 0.83 | GRIN1 (0.51) | MEN1KMT2APOLBCCR3 | |
| SCHEMBL4578958 | 0.82 | CCR3 (0.59) | MEN1KMT2APOLBCCR3HTR2A | |
| SCHEMBL14247372 | 0.81 | L3MBTL1 (0.69) | MEN1KMT2ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL4577591 | 0.79 | SMN1; SMN2 (0.66) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL27590237 | 0.78 | GRIN1 (0.52) | MEN1KMT2APOLBCCR3 | |
| SCHEMBL4775057 | 0.78 | SMN1; SMN2 (0.63) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL4958207 | 0.77 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2POLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | MEN1 2584/4885KMT2A 1234/4885SMN1; SMN2 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.